420 LEXINGTON AVE,, NEW YORK, NY
Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Ships First International Order of LYMPHIR™ to Europe
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Other Events
Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Q1
Q4
FY 2024
Q2
Amended Annual Report
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Definitive Additional Proxy Soliciting Materials
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence